BioCryst shares slide on trial suspension news

Shares of BioCryst Pharmaceuticals took a beating this morning after the company announced it was halting the intravenous drug arm of a cancer trial after finding particles in the treatment solution. Shares slipped 11 percent on the news that researchers had found particles in batches of Fodosine during a cancer trial. Early tests indicated that the particles came from the stopper used in packaging the drug and that it would not have a contaminating effect. The company alerted the FDA and suspended enrollment and treatment. Patients taking an oral version of Fodosine will continue in the trial.

- see this release from BioCryst
- read the AP report

Related Articles:
BioCryst seeks approval for flu trial, signs deal with Roche. Report
BioCryst gets fast-track status for avian flu drug. Report
BioCryst shares peak on hopes for bird flu drug. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.